Biontech presents positive preliminary phase 1/2 data for first-in-class car-t program bnt211 at aacr

Mainz, germany, april 11, 2022 (globe newswire) --  biontech se (nasdaq: bntx, “biontech” or “the company”) presented data from its ongoing first-in-human phase 1/2 trial evaluating the safety and preliminary efficacy of the company's novel car-t cell therapy candidate, bnt211, in patients with advanced solid tumors. the preliminary results demonstrated an encouraging safety profile and anti-tumor activity in testicular cancer patients at the first evaluated dose levels of bnt211. the data were presented in the clinical trials plenary session at the aacr annual meeting 2022 by prof. john haanen, m.d., ph.d., netherlands cancer institute (nki), amsterdam, netherlands.
BNTX Ratings Summary
BNTX Quant Ranking